IP Library Granted Patent US 11,273,143
Granted Patent B2
US 11,273,143 · App. 17/063,372 · Granted Mar 15, 2022

Nitroxyl donors with improved therapeutic index

Inventors: Vincent Jacob Kalish (Annapolis, MD); Frederick Arthur Brookfield (Abingdon, GB); Stephen Martin Courtney (Abingdon, GB); Lisa Marie Frost (Abingdon, GB); John P. Toscano (Glen Arm, MD)
Assignee: Cardioxyl Pharmaceuticals, Inc.
A61K31/341A61K9/0019A61K9/08A61K31/18A61K31/222A61K31/24A61K31/255A61K31/343A61K31/381A61K31/404A61K31/42A61K31/433A61K31/4436A61K31/538A61K31/5377A61K47/12A61K47/40A61P9/04C07C317/14C07D307/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,273,143
App. No.
17/063,372
Granted
Mar 15, 2022
Kind
B2
Abstract

The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.

Claims (11)

1. A method of treating pulmonary hypertension, comprising administering an effective amount of a compound of formula (1), or a pharmaceutical composition comprising the compound of formula (1), to a patient in need thereof, wherein the compound of formula (1) is represented by formula:

2. The method of claim 1 , wherein the compound or the pharmaceutical composition is administered intravenously.

3. The method of claim 2 , wherein the compound or the pharmaceutical composition is administered at a dose of at least 1 μg/kg/min.

4. The method of claim 2 , wherein the compound or the pharmaceutical composition is administered at a dose of at least 2.5 μg/kg/min.

5. The method of claim 2 , wherein the compound or the pharmaceutical composition is administered in an amount of at least 5 μg/kg/min.

6. The method of claim 2 , wherein the compound or the pharmaceutical composition is administered at a dose of at least 7.5 μg/kg/min.

7. The method of claim 2 , wherein the compound or the pharmaceutical composition is administered at a dose of at least 12 μg/kg/min.

8. The method of claim 2 , wherein the compound or the pharmaceutical composition is administered at a dose of at least 15 μg/kg/min.

9. The method of claim 2 , wherein the compound or the pharmaceutical composition is administered at a dose of no more than about 30 μg/kg/min.

10. The method of claim 2 , wherein the compound or the pharmaceutical composition is administered at a dose from about 1 μg/kg/min to about 100 μg/kg/min.

11. The method of claim 2 , wherein the compound or the pharmaceutical composition is administered at a dose from about 2.5 μg/kg/min to about 100 μg/kg/min.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 16, 2020
From: KALISH, VINCENT JACOB; BROOKFIELD, FREDERICK ARTHUR; COURTNEY, STEPHEN MARTIN; FROST, LISA MARIE; TOSCANO, JOHN P.
To: CARDIOXYL PHARMACEUTICALS, INC.
Reel/Frame 054081/0226 →
Continuity (10)
Continuation 16724657 · Dec 23, 2019
Continuation 16242139 · Jan 8, 2019
Continuation 15960993 · Apr 24, 2018
Continuation 15430946 · Feb 13, 2017
Continuation 14880173 · Oct 9, 2015
Continuation 14641377 · Mar 7, 2015
Continuation 14158456 · Jan 17, 2014
Provisional Application 61782781 · Mar 14, 2013
Provisional Application 61754237 · Jan 18, 2013
Related Publication 20210015784A1 · Jan 21, 2021
Cited By (1)
US 12,186,301